The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Open accessAbstract
To compare the ability of different cytokines and other molecules to enhance the immunogenicity of tumor cells, we generated 10 retroviruses encoding potential immunomodulators and studied the vaccination properties of murine tumor cells transduced by the viruses. Using a B16 melanoma model, in which irradiated tumor cells alone do not stimulate significant anti-tumor immunity, we found that irradiated tumor cells expressing murine granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulated potent, long-lasting, and specific anti-tumor immunity, requiring both CD4+ and CD8+ cells. Irradiated cells expressing interleukins 4 and 6 also stimulated detectable, but weaker, activity. In contrast to the B16 system, we found that in a number of other tumor models, the levels of anti-tumor immunity reported previously in cytokine gene transfer studies involving live, transduced cells could be achieved through the use of irradiated cells alone. Nevertheless, manipulation of the vaccine or challenge doses made it possible to demonstrate the activity of murine GM-CSF in those systems as well. Overall, our results have important implications for the clinical use of genetically modified tumor cells as therapeutic cancer vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,658
Dialynas, D. P., Quan, Z. S., Wall, K. A., Pierres, A., Quintáns, J., Loken, M. R., Pierres, M., & Fitch, F. W. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.5.2445 · Cited by 1,273
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122
Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., & Frost, P. (1990) · Cell · doi:10.1016/0092-8674(90)90591-2 · Cited by 916
Self-citationDanos, O., & Mulligan, R. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.17.6460 · Cited by 875
Self-citationSarmiento, M., Glasebrook, A. L., & Fitch, F. W. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.6.2665 · Cited by 802
Murine interleukin-4 displays potent anti-tumor activity in vivo
Tepper, R. I., Pattengale, P. K., & Leder, P. (1989) · Cell · doi:10.1016/0092-8674(89)90925-2 · Cited by 778
Klein, G., Sjögren, H. O., Klein, E., & Hellström, K. E. (1960) · PubMed · Cited by 742
Cited by
Items 101–175 of 175
Thomas, A. M., Santarsiero, L. M., Lutz, E. R., Armstrong, T. D., Chen, Y.-C., Huang, L.-Q., Laheru, D. A., Goggins, M., Hruban, R. H., & Jaffee, E. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031435 · Cited by 347
Self-citationRakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Laheru, D., Lutz, E., Burke, J., Biedrzycki, B., Solt, S., Onners, B., Tartakovsky, I., Nemunaitis, J., Le, D., Sugar, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0371 · Cited by 346
Self-citationInhibition of tumor growth by elimination of granulocytes.
Pekarek, L. A., Starr, B. A., Toledano, A. Y., & Schreiber, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.435 · Cited by 340
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 336
The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy
Galili, U. (2005) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2005.01366.x · Cited by 336
Strategies for designing and optimizing new generation vaccines
Berzofsky, J. A., Ahlers, J. D., & Belyakov, I. M. (2001) · Nature Reviews Immunology · doi:10.1038/35105075 · Cited by 334
Dranoff, G. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18813.x · Cited by 334
Self-citationImmunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Butterfield, L. H., & Najjar, Y. G. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 330
Disis, M., Bernhard, H., Shiota, F., Hand, S., Gralow, Jr., Huseby, E., Gillis, S., & Cheever, M. (1996) · Blood · doi:10.1182/blood.v88.1.202.202 · Cited by 329
Todryk, S., Melcher, A. A., Hardwick, N., Linardakis, E., Bateman, A., Colombo, M. P., Stoppacciaro, A., & Vile, R. G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1398 · Cited by 328
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
Yamanaka, R., Homma, J., Yajima, N., Tsuchiya, N., Sano, M., Kobayashi, T., Yoshida, S., Abe, T., Narita, M., Takahashi, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0120 · Cited by 325
Slingluff, C. L., Petroni, G. R., Yamshchikov, G. V., Barnd, D. L., Eastham, S., Galavotti, H., Patterson, J. W., Deacon, D. H., Hibbitts, S., Teates, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.005 · Cited by 322
Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor
Armitage, J. O. (1998) · Blood · doi:10.1182/blood.v92.12.4491 · Cited by 321
Yeo, T. P., Hruban, R. H., Leach, S. D., Wilentz, R. E., Sohn, T. A., Kern, S. E., Iacobuzio-Donahue, C. A., Maitra, A., Goggins, M., Canto, M. I., et al. (2002) · Current Problems in Cancer · doi:10.1067/mcn.2002.129579 · Cited by 321
Self-citationKinoshita, S., Su, L., Amano, M., Timmerman, L. A., Kaneshima, H., & Nolan, G. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80326-x · Cited by 318
Cancer immunotherapy with mRNA‐transfected dendritic cells
Gilboa, E., & Vieweg, J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00139.x · Cited by 316
Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012142 · Cited by 314
The Sentinel Within: Exploiting the Immune System for Cancer Biomarkers
Anderson, K. S., & LaBaer, J. (2005) · Journal of Proteome Research · doi:10.1021/pr0500814 · Cited by 314
Swift, S., Lorens, J., Achacoso, P., & Nolan, G. P. (1999) · Current Protocols in Immunology · doi:10.1002/0471142735.im1017cs31 · Cited by 313
van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 309
Yu, W.-D., Sun, G., Li, J., Xu, J., & Wang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.048 · Cited by 308
Chemokines and their role in tumor growth and metastasis
Wang, J. M., Deng, X., Gong, W., & Su, S. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00128-8 · Cited by 308
Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J.-S., Falls, T., Burns, J., Garcia, V., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305
Soiffer, R., Hodi, F. S., Haluska, F., Jung, K., Gillessen, S., Singer, S., Tanabe, K., Duda, R., Mentzer, S., Jaklitsch, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.005 · Cited by 305
Self-citationKim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M. S., Je, J. E., Yoon, J. H., Thorne, S. H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.008 · Cited by 303
Rittenhouse, H. G., Finlay, J. A., Mikolajczyk, S. D., & Partin, A. W. (1998) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408369891234219 · Cited by 303
A new dawn for eosinophils in the tumour microenvironment
Grisaru-Tal, S., Itan, M., Klion, A. D., & Munitz, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0283-9 · Cited by 302
Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs
Kündig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J. L., Battegay, M., Lother, H., Gessner, A., Kühlcke, K., Ohashi, P. S., Hengartner, H., et al. (1995) · Science · doi:10.1126/science.7761853 · Cited by 301
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M. P., & Rivoltini, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl158 · Cited by 300
Tumor-infiltrating T lymphocytes: Friends or foes?
Yu, P., & Fu, Y.-X. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700389 · Cited by 299
Slingluff, C. L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318233e5b2 · Cited by 299
J�ger, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., J�ger, D., Ilsemann, C., Hagedorn, M., Oesch, F., & Knuth, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960703)67:1<54::aid-ijc11>3.0.co;2-c · Cited by 299
Barba, D., Hardin, J., Sadelain, M., & Gage, F. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4348 · Cited by 297
Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F. S., Jaklitsch, M., Mentzer, S., Swanson, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.091 · Cited by 296
Self-citationCurrent Developments in Cancer Vaccines and Cellular Immunotherapy
Ribas, A., Butterfield, L. H., Glaspy, J. A., & Economou, J. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.041 · Cited by 295
Adler, A. J., Marsh, D. W., Yochum, G. S., Guzzo, J. L., Nigam, A., Nelson, W. G., & Pardoll, D. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1555 · Cited by 294
Self-citationInduction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 294
Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Bazin, H., Tielemans, F., Leo, O., Urbain, J., & Moser, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240317 · Cited by 291
Menezes, S., Melandri, D., Anselmi, G., Perchet, T., Loschko, J., Dubrot, J., Patel, R., Gautier, E. L., Hugues, S., Longhi, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.12.001 · Cited by 291
Bandara, G., Mueller, G. M., Galea-Lauri, J., Tindal, M. H., Georgescu, H. I., Suchanek, M. K., Hung, G. L., Glorioso, J. C., Robbins, P. D., & Evans, C. H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10764 · Cited by 290
Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9461 · Cited by 286
Andoniou, C. E., van Dommelen, S. L. H., Voigt, V., Andrews, D. M., Brizard, G., Asselin-Paturel, C., Delale, T., Stacey, K. J., Trinchieri, G., & Degli-Esposti, M. A. (2005) · Nature Immunology · doi:10.1038/ni1244 · Cited by 285
Golgher, D., Jones, E., Powrie, F., Elliott, T., & Gallimore, A. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11<3267::aid-immu3267>3.0.co;2-1 · Cited by 282
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
Waitz, R., Solomon, S. B., Petre, E. N., Trumble, A. E., Fassò, M., Norton, L., & Allison, J. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1782 · Cited by 282
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Locy, H., de Mey, S., de Mey, W., De Ridder, M., Thielemans, K., & Maenhout, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02909 · Cited by 279
New targets and approaches in osteosarcoma
Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 273
Butterfield, L. H. (2015) · BMJ · doi:10.1136/bmj.h988 · Cited by 272
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
“Immune responses against many of the class I-restricted epitopes, as measured by both ELIspot and frequency of tetramer-reactive cells, were significantly lower in the GM-CSF arm.”
BackgroundInfluentialYoung, J. W., & Inaba, K. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.7 · Cited by 269
Tumour–induced immune modulation of sentinel lymph nodes
Cochran, A. J., Huang, R.-R., Lee, J., Itakura, E., Leong, S. P. L., & Essner, R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1919 · Cited by 268
The promise of cancer vaccines
Gilboa, E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1359 · Cited by 267
GM-CSF: A Double-Edged Sword in Cancer Immunotherapy
Kumar, A., Taghi Khani, A., Sanchez Ortiz, A., & Swaminathan, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901277 · Cited by 265
Yamanaka, R., Abe, T., Yajima, N., Tsuchiya, N., Homma, J., Kobayashi, T., Narita, M., Takahashi, M., & Tanaka, R. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601268 · Cited by 265
Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy
Bhattacharya, P., Budnick, I., Singh, M., Thiruppathi, M., Alharshawi, K., Elshabrawy, H., Holterman, M. J., & Prabhakar, B. S. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0149 · Cited by 264
Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy
Liu, J.-Q., Zhang, C., Zhang, X., Yan, J., Zeng, C., Talebian, F., Lynch, K., Zhao, W., Hou, X., Du, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.021 · Cited by 262
Huffman, J. A., Hull, W. M., Dranoff, G., Mulligan, R. C., & Whitsett, J. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118461 · Cited by 262
Self-citationWilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14184 · Cited by 259
Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells
Tepper, R. I., & Mulé, J. J. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.2-153 · Cited by 254
Balance of MafB and PU. 1 specifies alternative macrophage or dendritic cell fate
Bakri, Y., Sarrazin, S., Mayer, U. P., Tillmanns, S., Nerlov, C., Boned, A., & Sieweke, M. H. (2005) · Blood · doi:10.1182/blood-2004-04-1448 · Cited by 187
Meta-analysis. Beyond the grand mean?
Smith, G. D., Egger, M., & Phillips, A. N. (1997) · BMJ · doi:10.1136/bmj.315.7122.1610 · Cited by 174
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Ruf, P., & Lindhofer, H. (2001) · Blood · doi:10.1182/blood.v98.8.2526 · Cited by 174
Favre, D., Blouin, V., Provost, N., Spisek, R., Porrot, F., Bohl, D., Marmé, F., Chérel, Y., Salvetti, A., Hurtrel, B., et al. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11605-11611.2002 · Cited by 150
Favre, D., Provost, N., Blouin, V., Blancho, G., Chérel, Y., Salvetti, A., & Moullier, P. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0494 · Cited by 122
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
Agha‐Mohammadi, S., O'Malley, M., Etemad, A., Wang, Z., Xiao, X., & Lotze, M. T. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.566 · Cited by 110
The ReNAissanCe of mRNA-based cancer therapy
Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.957685 · Cited by 95
“Previously, it has been described that GM-CSF could augment immune responses [108,109].”
BackgroundTumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
Sivaram, N., McLaughlin, P. A., Han, H. V., Petrenko, O., Jiang, Y.-P., Ballou, L. M., Pham, K., Liu, C., van der Velden, A. W. M., & Lin, R. Z. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123540 · Cited by 78
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Jiang, Q., Braun, D. A., Clauser, K. R., Ramesh, V., Shirole, N. H., Duke-Cohan, J. E., Nabilsi, N., Kramer, N. J., Forman, C., Lippincott, I. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.046 · Cited by 68
Vaccine therapy for pancreatic cancer
Salman, B., Zhou, D., Jaffee, E. M., Edil, B. H., & Zheng, L. (2013) · OncoImmunology · doi:10.4161/onci.26662 · Cited by 64
Self-citationModular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy
Ji, P., Sun, W., Zhang, S., Xing, Y., Wang, C., Wei, M., Li, Q., Ji, G., & Yang, G. (2023) · Advanced Science · doi:10.1002/advs.202301789 · Cited by 57
Deng, M., & Daley, G. Q. (2001) · Blood · doi:10.1182/blood.v97.11.3491 · Cited by 50
Pizzoferrato, E., Chu, N. R., Hawley, T. S., Lieu, F. H. L., Barber, B. H., Hawley, R. G., Watts, T. H., & Berinstein, N. L. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.18-2217 · Cited by 28
Metadata
- Authors
- Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1993-04-15
- Volume
- 90
- Issue
- 8
- Pages
- 3539-3543
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1991148746
- Cited by
- 2,818
- References
- 31
- FWCI
- 54.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.